Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice

BACKGROUND: The safety of pirfenidone on pulmonary fibrosis patients with other kinds of interstitial lung diseases (ILDs) in addition to idiopathic pulmonary fibrosis (IPF) is unknown. Furthermore, its effectiveness-related factors on IPF patients are not quite explored. METHODS: A retrospective st...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Chuling, Huang, Hui, Guo, Jian, Ferianc, Martin, Xu, Zuojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992179/
https://www.ncbi.nlm.nih.gov/pubmed/31999801
http://dx.doi.org/10.1371/journal.pone.0228390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992179/
https://www.ncbi.nlm.nih.gov/pubmed/31999801
http://dx.doi.org/10.1371/journal.pone.0228390

Ejemplares similares